CLDX
Celldex Therapeutics, Inc.Company Information
- Company Name
- Celldex Therapeutics, Inc.
- CIK
- CIK0000744218
- Category
- Large accelerated filer
- Ticker: Exchange
- CLDX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2835
- SIC Description
- In Vitro & In Vivo Diagnostic Substances
- Ticker
- CLDX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-11
- Last sale
- 2025-12-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 54,235
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 80,742,846
- Shares outstanding
- 77,840,000
- Ownership
- 103.73%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -5.87%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 47 | 36 | 29 | 36 | 23 | 17 | 28 | 36 | 43 | 115 | 35 | 21 | ||||||
| Marketable Securities Current | 670 | 416 | 490 | 547 | 607 | 656 | 697 | 720 | 760 | 709 | 389 | 214 | ||||||
| Accounts And Other Receivables Net Current | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | 3 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 8 | 14 | 21 | 18 | 19 | 21 | 22 | 8 | 9 | 5 | 10 | ||||||
| Assets Current | 725 | 459 | 535 | 604 | 648 | 694 | 747 | 779 | 812 | 835 | 432 | 246 | ||||||
| Property Plant And Equipment Net | 10 | 7 | 5 | 5 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 5 | 2 | 2 | 3 | 3 | 4 | 4 | 3 | 2 | 2 | 3 | 3 | ||||||
| Intangible Assets Net Excluding Goodwill | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | ||||||
| Other Assets Noncurrent | 15 | 15 | 13 | 9 | 9 | 10 | 10 | 10 | 0 | 0 | 0 | 0 | ||||||
| Assets | 782 | 511 | 583 | 648 | 692 | 739 | 792 | 823 | 846 | 869 | 466 | 280 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 15 | 10 | 1 | 4 | 2 | 3 | 3 | 1 | 4 | 3 | 3 | 4 | ||||||
| Accrued Liabilities Current | 44 | 38 | 47 | 40 | 28 | 25 | 34 | 28 | 19 | 18 | 22 | 18 | ||||||
| Operating Lease Liability Current | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Other Liabilities Current | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 4 | ||||||
| Liabilities Current | 61 | 51 | 51 | 46 | 33 | 32 | 40 | 32 | 28 | 26 | 31 | 28 | ||||||
| Operating Lease Liability Noncurrent | 3 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 0 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | ||||||
| Liabilities | 68 | 55 | 56 | 50 | 37 | 36 | 45 | 37 | 32 | 30 | 36 | 34 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,679 | 2,346 | 2,337 | 2,327 | 2,318 | 2,308 | 2,299 | 2,289 | 2,278 | 2,266 | 1,823 | 1,599 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 3 | 4 | 4 | 3 | 4 | 3 | 5 | 2 | 2 | 3 | 2 | ||||||
| Retained Earnings Accumulated Deficit | -1,966 | -1,893 | -1,814 | -1,733 | -1,666 | -1,609 | -1,555 | -1,508 | -1,466 | -1,430 | -1,397 | -1,354 | ||||||
| Stockholders Equity | 715 | 456 | 527 | 598 | 655 | 703 | 747 | 786 | 814 | 839 | 429 | 247 | ||||||
| Liabilities And Stockholders Equity | 782 | 511 | 583 | 648 | 692 | 739 | 792 | 823 | 846 | 869 | 466 | 280 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | 297 | ||||||
| Common Stock Shares Issued | 79 | 67 | 67 | 66 | 66 | 66 | 66 | 66 | 66 | 66 | 56 | 47 | ||||||
| Shares Outstanding | 79 | 67 | 67 | 66 | 66 | 66 | 66 | 66 | 66 | 66 | 56 | 47 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCelldex Therapeutics, Inc. (CLDX) — SEC Financial Statements & Analysis
Celldex Therapeutics, Inc. (CLDX) is a in vitro & in vivo diagnostic substances company, incorporated in DE. Celldex Therapeutics, Inc. trades on Nasdaq as: CLDX. Celldex Therapeutics, Inc. (CLDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Celldex Therapeutics, Inc. carries a market cap of $2.90B, a P/E ratio of -9.64x, a P/B ratio of 4.05x, a P/S ratio of 18448.58x, an enterprise value of $2.85B, and an EV/EBITDA multiple of -8.84x. On profitability, it posts an operating margin of -207534.39%, a net margin of -191432.48%, a Return on Equity (ROE) of -43.88%, a Return on Assets (ROA) of -40.76%, and a Return on Invested Capital (ROIC) of -50.14%. Per share, it reports EPS of $-3.86, diluted EPS of $-3.86, free cash flow per share of $-3.11, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -97.29% year-over-year, net income growth of 50.57% year-over-year, and EPS growth of 28.42% year-over-year. On the balance sheet, it maintains a current ratio of 11.82x, a quick ratio of 11.71x, working capital of $663.61M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.09, free cash flow of $-242.10M (TTM), and net debt of $-47.45M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.90B
- P/E TTM
- -9.64x
- EPS TTM
- $-3.86
- P/B TTM
- 4.05x
- ROE TTM
- -43.88%
- ROA TTM
- -40.76%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-242.10M
- Net Revenue TTM Growth 1Y
- -97.29%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Celldex Therapeutics, Inc. in?
Celldex Therapeutics, Inc. (CLDX) operates in the In Vitro & In Vivo Diagnostic Substances industry.
What exchange does CLDX trade on?
Celldex Therapeutics, Inc. (CLDX) trades on the Nasdaq.
Where is Celldex Therapeutics, Inc. incorporated?
Celldex Therapeutics, Inc. is incorporated in DE.
When was Celldex Therapeutics, Inc. (CLDX)'s most recent SEC filing?
Celldex Therapeutics, Inc. (CLDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is CLDX's market cap?
Celldex Therapeutics, Inc. (CLDX) has a market capitalization of $2.90B as of 2026-06-30.
What is CLDX's EPS (earnings per share)?
Celldex Therapeutics, Inc. (CLDX)'s trailing twelve month EPS is $-3.86 as of 2026-06-30.
What is CLDX's ROE (return on equity)?
Celldex Therapeutics, Inc. (CLDX)'s trailing twelve month Return on Equity (ROE) is -43.88% as of 2026-06-30.
What is CLDX's ROA (return on assets)?
Celldex Therapeutics, Inc. (CLDX)'s trailing twelve month Return on Assets (ROA) is -40.76% as of 2026-06-30.
What is CLDX's ROIC (return on invested capital)?
Celldex Therapeutics, Inc. (CLDX)'s trailing twelve month Return on Invested Capital (ROIC) is -50.14% as of 2026-06-30.
What is CLDX's EV/EBITDA?
Celldex Therapeutics, Inc. (CLDX)'s trailing twelve month EV/EBITDA is -8.84x as of 2026-06-30.